Human plasma proteins

Purification of human plasma proteins

The manufacture of human plasma derivatives started already during the Second World War when Cohn developed a plasma protein solution for the treatment of battlefield injuries. Since then, Cohn’s method, based on ethanol fractionation, has been widely used, however in the last decades supplemented with affinity chromatography.

A new-generation technology, based on affinity chromatography in expanded bed columns was presented a few years ago by the canadian company, Evolve Biologics.

Lihme Protein Solutions take the plasma fractionating technology even further by using our ChimerAds technology that is as effective and selective as expanded bed chromatography, but significantly cheaper.

Human plasma proteins

Plasma is the liquid content of blood (55 %) and is obtained after separation of white and red blood cells and platelets by centrifugation.

Plasma contains several proteins (approximately 60-80 mg/ml) including albumins (50-60 %),  immunoglobulins (10-20 %), clotting factors, C1 esterase inhibitor and alpha-1 proteinase inhibitor.

Plasma is collected from healthy human donors whereafter the proteins can be fractionated to give specific therapeutic proteins.


Human plasma proteins – the use

Plasma carries out a variety of functions in the body, including clotting blood, fighting diseases and other critical functions.

Fractionating the plasmaproteins results in specific proteins with great therapeutic value in treating a range of diseases, including immune deficiencies, autoimmune and neurological disorders, coagulation disorders, liver diseases, severe infections etc.

The ChimerAds technology is enabling fractionation of human plasma proteins for the biopharmaceutical industry